US Bancorp’s Metagenomi Therapeutics MGX Stock Holding History

US Bancorp’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.77K	Hold	4,500	–	–	﹤0.01%	3730
2026 Q2	$5.36K	Hold	4,500	–	–	﹤0.01%	3634
2026 Q1	$6.03K	Hold	4,500	–	–	﹤0.01%	3517
2025 Q4	$7.29K	Hold	4,500	–	–	﹤0.01%	3427
2025 Q3	$10.7K	Hold	4,500	–	–	﹤0.01%	3295
2025 Q2	$6.66K	Hold	4,500	–	–	﹤0.01%	3550
2025 Q1	$6.12K	Hold	4,500	–	–	﹤0.01%	3596
2024 Q4	$16.2K	Hold	4,500	–	–	﹤0.01%	3241
2024 Q3	$9.8K	Hold	4,500	–	–	﹤0.01%	3370
2024 Q2	$18.4K	Hold	4,500	–	–	﹤0.01%	3102
2024 Q1	$47.5K	Buy	+4,500	New	+$51.7K	﹤0.01%	2730

Other funds holding MGX

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

FAG

Fortitude Advisory Group Gig Harbor, Washington $262M AUM 30.62% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

US Bancorp's MGX Position: Q3 2026 in Review

US Bancorp held its Metagenomi Therapeutics (MGX) position steady in Q3 2026 at 4,500 shares worth $4.77K. The position accounts for ﹤0.01% of the portfolio, ranked #3730.

US Bancorp first reported a position in MGX in Q1 2024 and has held it in 11 quarters since. The position peaked at $47.5K in Q1 2024. 8 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

US Bancorp held 4,500 shares of Metagenomi Therapeutics worth $4.77K as of Q3 2026.
US Bancorp left its Metagenomi Therapeutics share count unchanged in Q3 2026.
Metagenomi Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #3730 holding.
US Bancorp first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 11 quarters since.
US Bancorp's Metagenomi Therapeutics position peaked at $47.5K in Q1 2024.
8 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.